Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
yes, you should enter a bid of 3 or 4.
but don't mess around with these $5 trades. Buy 100 million shares at 3 or 4.
All the other "longs" will think you're cool.
I like the way you "longs" keep saying "WHEN the buyout happens" instead of "IF the buyout happens." As if wishing could make it true.
How much debt do you think this company has right now? It was $18 million to the lenders and $900,000 to utilities and vendors the last time they disclosed their debt. What's your guess as to the current debt?
I mean "before the trial on Nov. 12th" of course.
What corners of the world are left? Are you talking String Theory?
I've seen PR's about DR-70 sales in pretty much every country on every continent, from 1996 through 2011 when the company ran out of money to buy PR's. But then I think the world only has two hemispheres. In the world created by you and the wolfman, there are more than two, as I recall.
Astellas is not "a private company looking to go public." Astellas is listed on the Tokyo exchange.
If Astellas wanted to get listed on a US exchange, there is NO WAY they would want to be listed on the lowest tier of the pinksheets. It is absurd to suggest that Astellas wants RXPC's listing.
Radient is deep in debt, with penalty/default interest accruing daily. Any private company wanting to get on the pinksheets can buy a shell with zero debt for under $500,000.
Conclusion: There is no suitor. There is no merger. There is no buyout. There is no takeover.
The Astellas rumor ALMOST had some weight in 2011 when Reyno joined the BOD. That weight disappeared when Reyno left the BOD in 2012:
"As previously disclosed in our recent filings, we have been experiencing severe working capital shortages. Unfortunately, this shortage has prevented us from being able to pay the premiums associated with our Director and Officer Insurance; consequently, two of our remaining directors, Mr. Lenard Reyno and Dr. Robert Beart, informed us that they must resign. As a result, we only have one independent director serving on our board at this time, Michael Boswell."
If Astellas wanted to acquire Radient and had been planning this acquisition since 2011, don't you think they could have paid those insurance premiums?
BTW, Boswell quit in 2013.
Simple - it means MacLellan has finished building his Fortress of Solitude.
He can't control the global cancer diagnostics market from Tustin. I think he is moving this multi-billion-dollar supercompany to Europe. Or Antarctica. Or the moon. Nothing is impossible for a multi-billion-dollar company with a blockbuster product like this one.
I am focusing on the present because that is all we have.
The present situation:
* buried in debt
* all employees let go 20 months ago
* company does not operate, does not file financials, does not manufacture anything
* the "coffers" are empty - they can't afford a PR
* they licensed Asia sales to UNI for only $100,000 per year and gave UNI rights to all the patents and intellectual property
* Class Action jury trial in eight days
As a result, there is no possibility of a takeover, buyout, or merger. The debt alone is prohibitive. Anyone who wants to manufacture or sell the test needs only to license it from MacLellan. This company is never going to operate again without bankruptcy first.
That is not the kind of "present as it affects the future" you want to hear, but that is the truth. You prefer rumors and fantastic multi-billion-dollar fairy tales, fine, but don't expect everyone to share your "vision."
RXPC stopped itself in 2009 when the company lost Jade.
Radient isn't a typical pinksheet stock? Is there a typical pinksheet stock?
Many pinksheet stocks operate a business, report financial earnings, and release PR's. If those are "typical," then I agree, RXPC is atypical.
This stock hit .0003 in March and April because SRL released news about selling DR-70 tests in India. SRL was selling their tests at $44 USD apiece, which is less than half price. If SRL releases another news article, then yes, you might see .0003 again.
You say "Once merger news goes through, especially with some of the names being tossed around here...." The problems with that statement are:
1. You say "Once" as if it were fact. It is just a rumor -- you should say "IF."
2. The same buyout/merger/takeover rumor has been perpetuated since early 2011. The company has gone through a lot of changes in the past 30 months -- a buyout/merger/takeover is so unlikely now that it seems absurd to even mention it. Unfortunately, the "longs" have nothing else to hope for.
3. Tossing around names of potential takeover companies is a fun game to play, but has no relevance. I think the word "tossing" is diagnostic.
Highliandmike, I am not saying you can't make money on pinksheet stocks.
I am refuting the claims of dcspka who asserts that "Important People" are accumulating RXPC stock in an effort to take over the company.
The Pinksheets are unregulated and unpredictable. You can't always be sure a pinksheet company is even operating. Pinksheet stocks are like pyramid schemes, but then, isn't all of Wall Street one big complicated pyramid scheme?
If you buy this stock at .0001 and sell for a profit, congratulations. Some people have made small fortunes on this stock, especially when it was on the AMEX, even though the company has basically been dead since 2009 when they lost control of Jade.
I object, however, to people trying to move the PPS by spreading unsubstantiated rumors about mergers/buyouts and GCDx selling the test on the internet. I think that is unethical and dishonest and I'm not going to stand by and let that kind of dishonesty go unchallenged.
What 8-K are you talking about?
You ask "So the 8k is false information?" and my response is, no, the 8-K's are all true. The false information consists of:
1. The rumor about a takeover or merger.
2. The conjecture about GCDx having a license to manufacture and/or sell the test.
3. The assertion that UNI will pay Radient more than $100,000 per year.
Please explain which 8-K you are referring to.
Saying that nobody is shorting this stock at .0001 is not the same as saying "it's impossible."
If short-sellers wanted to short RXPC, they would wait for, or create, momo and run it up a few ticks and THEN short it. That's Pinksheet Manipulation 101: Cover, let it run up again, and short it again.
There's no money to be made by shorting a stock at .0001, especially a stock where $5000 traded is a "huge day."
When the lenders convert, their trades are unresolved for a day and it shows up on REGSHO. I think that some here have misinterpreted that as shorting.
And if there is no news about a merger agreement after the trial....
Will you admit that there is no merger agreement?
You say that "People have to understand that the in-vitro diagnostic industry is a market valued in the tens of billions and Onko-Sure has the best test out there approved by the FDA!"
Are you aware that the test is only cleared by the FDA for use in conjunction with CEA, and ONLY for monitoring CRC?
And are you aware that the FDA clearance has lapsed?
When you say "No other test can come close. It's a documented fact," what do you mean? Come close to what? What documented facts are you talking about?
DR-70 can't tell you where in the body the cancer may be, can't tell you the stage its in, and the best specificity it has ever measured was 95%, which means it has a 5% false positive rate. All the hype regarding DR-70 hints at using the test as a screener, but MacLellan himself said that 95% specificity is too low for a screener.
I think you need to tell some doctors how great DR-70 is, because globally, doctors do not agree with you -- and that is why revenues have never gotten higher than about 10% of operatign costs and never higher than 5% of guidance. The CEO stopped giving guidance after missing by such a large margin several times, unless you count the "India Dea," where guidance was $12 million and revenues were about $50,000.
I agree with one thing you said: "Do your DD, people."
Yes I am sure.
THRR has several patents for aluminum casting processes.
LLBO has the patent for the First Warning Device.
So what? Haven't you learned yet that a patent is worth nothing if the device doesn't generate revenues?
Important People do not own pinksheet stocks.
Traders gamble on them, and bagholders hold them wondering what to do when their stock turns out to be a failure, but Important People don't buy, trade, or hold pinksheet stocks.
After the trial is over, what will your NEW excuse be for the delay of news?
you have no proof of a merger agreement.
Yet you keep referring to "the merger agreement" or "the takeover" as if it were a foregone conclusion. That is unethical, IMO.
In early 2011 when you and wolfman started the takeover rumor, RPC may have been a candidate for a takeover.
1. They still had $20 million Jade equity on their books.
2. The India Deal was supposedly going to bring $12 million into Radient's "coffers."
3. The O/S was only about 50 million shares.
4. They were listed on the AMEX.
5. Radient had a bricks-and-morter business operating and they
were manufacturing the device.
6. They were working out a deal to get rid of the debt.
7. NuVax was operating, to our knowledge, and developing CIT and Chang's newer cancer vaccine technology.
Today,
1. The SEC forced Radient to admit that the Jade equity was $0.
2. The India Deal was proven to be false.
3. The O/S is at least 4.5 Billion shares.
4. they are listed on the lowest tier of the pinksheets.
5. Radient does not have a bricks-and-mortar business operating and they are not manufacturing anything.
6. They never got rid of the debt. All loans are in default and accruing penalty interest.
7. NuVax is not operating, Chang left when Radient stopped paying him, and Radient stated on their last 10-K that CIT was worth nothing.
Radient is not a takeover candidate, IMO. No entity has any reason to merger with or take over Radient. If they want to manufacture or sell onko-sure, they can pay $100,000 a year for a license like the UNI license.
of course they do.
dcspka, show ONE ticker symbol that still ends in PK
the PK extension was removed from ALL pinksheet stocks at the same time.
It was not recent, and it was not specific to RXPC. The OB was also removed from OTCBB stocks at the same time.
Hope that clears up your confusion.
RXPC is on the lowest tier of the pinksheets. On this tier, stocks do not have to file, report, or even operate. Check out KKUR, LLBO, THRR, and a hundred others like them.
I made the comment earlier that "I wish the SEC had not removed the PK extensions -- it served as a warning to newbies." Thanks for proving me right, dcspka.
The case can't be dismissed. A Jury will hear the case.
There is no fine. It's a jury trial.
What do you mean, the court won't "comb through the evidence?" The lawyers present whatever evidence they want to present to the jury. nobody is combing through anything.
I think you are talking about a different trial entirely? Maybe you are on the wrong MB? Radient's trial is 11 days away, not 14.
The misinformation on this MB is puzzling. What do you and blackpantherz hope to gain from it? The only thing that will move this stock is news. It doesn't have to be real news -- it can be hype -- but it has to be released on prnewswire or one of the other news services.
A/S is 5 billion.
the last time the TA released the O/S it was 4.5 billion (many weeks ago). The TA is now refusing to give out the number.
you can try contacting the TA yourself -- find them here:
http://www.otcmarkets.com/stock/RXPC/company-info
Not sure why you are so smug. As a member of the Class Action, you have seen your investment go from $27 PPS to 0.0001 PPS.
That is epic.
you need to read THAT study too.
"The cancer diagnosis has as main objectives to know the localization (place) and also to identify the stage (stage) and the histological characterization (kind). The knowledge of the place, stage and kind will help to define the treatment and will determine the survival and the clinic success."
bad news -- DR-70 does not achieve that goal because it does not tell you the place, stage, OR kind.
I love the irony.
you need to read the results of that study.
"Aims: The aims of this study were to evaluate the role of DR-70 immunoassay in suspected malignant PE."
"Conclusions: DR-70.... has no role in differentiating malignant PE from non-malignant PE."
They tossed in a vague statement about lung cancer but to a scientist that is meaningless. This is a failure to meet endpoint, a failure to prove a hypothesis, a FAILURE.
Nobody bought RXPC because of this article.
RXPC can't publicly respond to anyone or anything because PR's cost money and Radient has no money.
Radient responded to Rosen's claims in front of a judge. You should read it.
Radient hasn't released any info to its shareholders other than SEC filings for two years. The significance of this apparently has not sunk in yet for some "longs."
dcspka, onko-sure has no commercial value. Revenues have never come CLOSE to manufacturing/marketing/administrative costs.
CIT is worthless, according to Radient in their last 10-K. They state in the 10-K that CIT is not worth developing, and they list the reasons. Can't be any more specific than that.
You don't believe the 10-K. That is your choice. Good luck with that investment strategy. I think one glance at your RXPC "position" in your brokerage account tells the whole story, but I suppose you don't believe that either?
MVSS will do what?
Let me guess, those Certified Letters will arrive in court attached with silver thread to the wings of flying pigs.
what is "aphillyation?"
And who are "the Pharm Animals?"
And why could anyone else be sued? Radient the corporation is being sued for releasing the PR and Mac is being sued for writing that PR.
Are you trying to say there is a merger or buyout that started in early 2011 and is still active? The entity buying or merging with Radient has quietly been allowing default and penalty interest to accrue for 30 months because.... why? That does not seem like good business.
what does "boost stock" mean to you?
if you mean "issue shares..." the A/S is 5 billion and the O/S is 4.5 billion the last time the TA released the O/S number. Radient issued a LOT of shares in a short time period right before they stopped releasing the O/S number. Very doubtful that there are many shares left to "boost." Possibly none.
Even of there are 500 million shares available to print, that is only $50,000 at market prices. $50k won't pay for much lawyerin' and it sure won't pay for any type of award.
You were aware that the A/S is 5 billion and the O/S is at least 4.5 billion, I assume? If you didn't know that.... my condolences.
you are not sharing "knowledge."
You are sharing something else.
Earnings season?
There is no earnings season in the pinksheets.
I'm questioning whether you realize what kind of stock you're dealing with here. The old PK ticker extension was meant to help newbies stay away from this kind of stock. I don't know why they got rid of that PK extension.
If RXPC changes to RXPCQ, do you know what that means?
And what does "reversal" mean, to you? There is nothing to "reverse" yet. Are you saying you think that if Radient loses the CA they will appeal?
Considering that RXPC is about to become a multi-billion-dollar powerhouse in the arena of global cancer diagnostics.....
The total award will be one zillion dollars.
UNI, Fortis, Astellas, SRL, Gartner, and Obamacare will all pitch in to pay for it.
Better send in your paperwork, dcspka. You are the only person so far who has admitted to buying in that timeframe and being a Member of the Class. If you are the only person sending in your paperwork.... you might get a crisp $20 bill, which is more than you're ever going to get for your RXPC shares.
Unless you can talk blackpantherz into buying your "position." He's kind of giddy about his secret news. Put your shares in a SELL order for a penny and maybe the Panther will buy them in a fat-finger trade.
WHO can't release certain info publicly?
This "News" you're talking about is private? Yet YOU somehow have knowledge of this "News?" That makes you an insider, breaking SEC rules on this humble little message board? I guess you want us to say "Thank you."
But if you know about secret good news, why aren't you buying hundreds of millions of shares? Seems like you should just keep quiet about your blockbuster news and buy all you can at any price.
Do you think the takeover is delayed by the trial?
If that is the case... when the trial ends, the takeover will happen. No more delays or excuses.
Which means that when the trial ends and the takeover still doesn't happen, you will admit that the takeover story is just a fairy tale?
here is a link proving that Rosen is behind the class action.
This is the initial PR from March 2011. They ALL start like this.
http://www.reuters.com/article/2011/03/12/idUS28777+12-Mar-2011+MW20110312
"The Rosen Law Firm, P.A. today announced it has filed a class action lawsuit on behalf of investors who purchased the common stock of Radient Pharmaceuticals Corporation ("Radient" or the "Company") (NYSE Amex: RPC) during the period between January 18, 2001 and March 4, 2011, inclusive (the "Class Period"), seeking to recover damages for violations of federal securities laws."
This is how basically EVERY stock class action starts. The law firm decides it's an ambulance worth chasing. They file the case, which doesn't cost much.
"If you wish to serve as lead plaintiff, you must move the Court no later than May 10, 2011. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. "
Rosen did not have a lead plaintiff when he filed. Rosen cannot be the lead plaintiff because he did not buy RPC stock in the Class period, so he needs someone to be the lead plaintiff. Nguyen did not "hire" Rosen. The lead plaintiff has to appear in court, prove he or she bought the stock in the class period, and other do other things -- For that effort, the LP gets a bigger slice of the pie, IF there is an award -- but not as big as the lawyer's slice.
dcspka, please do a little research about this type of Class Action before posting again about how Nguyen sought out Rosen and hired him. Ignorance can be cured.
If their last name was Smith or Johnson, would you be asking that question?
Because Nguyen is as common a name as Smith or Johnson.
Nothing confusing about any of this.
There is no soon-to-be-realized takeover of RXPC.
Rosen is behind the class action lawsuit.
Nobody is going to benefit in any way, EVER, from RXPC. it's dead and onko-sure is a complete failure. UNI is not going to make any money selling onko-sure because the global medical community has rejected onko-sure.
The only person who stands a chance of making money on onko-sure is Gartner, but his profits would not come from selling onko-sure -- his profits would come from fools who fund his company. Unfortunately for Gartner, fools like that are uncommon. He found one fool investor last year but that fool got smart and bailed out.
I think you, jimtash, and the Wolfman should give money to Gartner. You are exactly the kind of "investors" he is looking for.
Your point makes no sense.
18 million shares translates into $1800. For the entire DAY. MM's flip $1800 worth of stock around without batting an eyelash. That is the same thing as zero in my book.
If 50 million shares are traded in a day, the "longs" would shout about the "huge volume" but that is only $5000. Seriously, how often do you make trades worth $5000 or less?
And what is "worse" than bankruptcy, may I ask? This company is already so far in debt that they will never, and I mean NEVER, get out of debt. They haven't filed a 10-Q or 10-K since the 2011 10-K. They don't operate. They laid off all the employees except two officers, MacLellan and Boswell, and Boswell since quit.
But there is no certainty of bankruptcy in the pinksheets. Many of these zombies trade long after the PR machine shuts off. I can name a dozen off the top of my head. Filing for bankruptcy would be the ethical thing to do here -- far better companies than this have filed for bankruptcy - but this zombie may stagger on for years. Apparently nobody cares enough to hit it with a shovel and bury it.
Look at AXMP. That is MacLellan's Chinese company. Apparently they're never going to bury that one either.
18 million shares is $1800.
Is you point that 18 million shares is a lot of shares, or is NOT a lot of shares?
I think the volume in this stock is typical of pinksheet zombies. There is no buying interest in this kind of stock without some hype. There hasn't been hype here since SRL sold DR-70 tests for half price in India.
My favorite part of the Motion document:
it contains excerpys from previous drafts of the January PR. One previous draft said this:
"Collaboration with Mayo is critically important to the commercialization strategy and plan for Onko-Sure. To have internationally recognized leaders in oncology evaluate Onko-Sure is a testament to the importance of our test. It is also a boost for RPC to be involved and collaborate with such a prestigious cancer center like Mayo."
The final draft removed those references to Mayo and said this:
"... the consistent feedback we’ve received in regards to the long-term potential of Onko-Sure test has been
overwhelmingly positive. To have internationally recognized leaders in oncology take such great interest in Onko-Sure is a testament to the importance of the test...."
And the judge's comments about that wording:
"There is only one internationally recognized leader in oncology mentioned by name in the January 18 Press Release—Mayo Clinic. But the passage in bold is not a reference to Mayo, according to Radient. See DF 66. It instead refers to other, unnamed, internationally recognized leaders in oncology. "
BUSTED, IMO.
They tried marketing DR-70 in Canada for lung cancer.
For years.
it failed.
It's obvious that the Mayo never touched DR-70.
The Street article is responsible for what? minimizing the damage?
If Radient is innocent, the Street was simply clarifying what everyone supposedly should have already known.